Thus, these investigations introduced a new research scenario encouraging the analysis of Gremlin-1 overexpression in other pathological conditions, such as in patients with NAFLD on liver biopsy and in patients with type 2 diabetes mellitus and metabolic syndrome [34]. This evidence concerns the gene GREM1 and metabolic dysfunction-associated steatotic liver disease.